SERA PROGNOSTICS, INC. Research and Development Expense
SERA PROGNOSTICS, INC. (SERA) reported Research and Development Expense of $3.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- SERA PROGNOSTICS, INC. research and development expense for the quarter ending 2026-06-30 was $3.49M, a 4.67% increase year-over-year.
- SERA PROGNOSTICS, INC. research and development expense for the quarter ending 2026-03-31 was $3.03M, a 9.12% decline year-over-year.
- SERA PROGNOSTICS, INC. research and development expense for the quarter ending 2025-12-31 was $3.22M, a 2.45% increase year-over-year.
- SERA PROGNOSTICS, INC. research and development expense for the quarter ending 2025-09-30 was $3.28M, a 6.23% decline year-over-year.
- SERA PROGNOSTICS, INC. research and development expense for fiscal 2025 was $13.17M, a 10.58% decline from fiscal 2024.
- SERA PROGNOSTICS, INC. research and development expense for fiscal 2024 was $14.73M, a 3.25% decline from fiscal 2023.
- SERA PROGNOSTICS, INC. research and development expense for fiscal 2023 was $15.22M, a 6.89% increase from fiscal 2022.
- SERA PROGNOSTICS, INC. research and development expense for fiscal 2022 was $14.24M, a 29.27% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.49M 10-Q · filed 2026-08-12 | $6.52M 10-Q · filed 2026-08-12 | $9.74M derived: sum of 3 quarters · filed 2026-08-12 | $13.02M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.03M 10-Q · filed 2026-05-06 | $6.25M derived: sum of 2 quarters · filed 2026-05-06 | $9.53M derived: sum of 3 quarters · filed 2026-05-06 | $12.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $6.50M derived: sum of 2 quarters · filed 2026-03-18 | $9.84M derived: sum of 3 quarters · filed 2026-08-12 | $13.17M 10-K · filed 2026-03-18 |
| 2025-09-30 | $3.28M 10-Q · filed 2025-11-13 | $6.62M derived: sum of 2 quarters · filed 2026-08-12 | $9.96M 10-Q · filed 2025-11-13 | $13.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.34M 10-Q · filed 2026-08-12 | $6.67M 10-Q · filed 2026-08-12 | $9.81M derived: sum of 3 quarters · filed 2026-08-12 | $13.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.33M 10-Q · filed 2026-05-06 | $6.47M derived: sum of 2 quarters · filed 2026-05-06 | $9.97M derived: sum of 3 quarters · filed 2026-05-06 | $14.38M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $6.64M derived: sum of 2 quarters · filed 2026-03-18 | $11.05M derived: sum of 3 quarters · filed 2026-03-18 | $14.73M 10-K · filed 2026-03-18 |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-13 | $7.91M derived: sum of 2 quarters · filed 2025-11-13 | $11.59M 10-Q · filed 2025-11-13 | $15.49M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $4.41M 10-Q · filed 2025-08-06 | $8.09M 10-Q · filed 2025-08-06 | $11.98M derived: sum of 3 quarters · filed 2025-08-06 | $15.52M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $3.68M 10-Q · filed 2025-05-07 | $7.58M derived: sum of 2 quarters · filed 2025-05-07 | $11.12M derived: sum of 3 quarters · filed 2025-05-07 | $14.80M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $7.43M derived: sum of 2 quarters · filed 2025-03-19 | $11.12M derived: sum of 3 quarters · filed 2025-03-19 | $15.22M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.54M 10-Q · filed 2024-11-06 | $7.23M derived: sum of 2 quarters · filed 2024-11-06 | $11.33M 10-Q · filed 2024-11-06 | $14.81M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.69M 10-Q · filed 2024-08-07 | $7.79M 10-Q · filed 2024-08-07 | $11.28M derived: sum of 3 quarters · filed 2024-08-07 | $15.45M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $4.10M 10-Q · filed 2024-05-08 | $7.59M derived: sum of 2 quarters · filed 2024-05-08 | $11.76M derived: sum of 3 quarters · filed 2024-05-08 | $15.03M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $7.66M derived: sum of 2 quarters · filed 2024-03-20 | $10.92M derived: sum of 3 quarters · filed 2024-03-20 | $14.24M 10-K · filed 2024-03-20 |
| 2022-09-30 | $4.18M 10-Q · filed 2023-11-08 | $7.44M derived: sum of 2 quarters · filed 2023-11-08 | $10.76M 10-Q · filed 2023-11-08 | $13.83M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $3.26M 10-Q · filed 2023-08-09 | $6.58M 10-Q · filed 2023-08-09 | $9.66M derived: sum of 3 quarters · filed 2023-08-09 | $12.38M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $3.32M 10-Q · filed 2023-05-10 | $6.40M derived: sum of 2 quarters · filed 2023-05-10 | $9.12M derived: sum of 3 quarters · filed 2023-05-10 | $11.95M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $5.80M derived: sum of 2 quarters · filed 2023-03-22 | $8.62M derived: sum of 3 quarters · filed 2023-03-22 | $11.02M 10-K · filed 2023-03-22 |
| 2021-09-30 | $2.72M 10-Q · filed 2022-11-09 | $5.55M derived: sum of 2 quarters · filed 2022-11-09 | $7.94M 10-Q · filed 2022-11-09 | $10.04M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.82M 10-Q · filed 2022-08-10 | $5.22M 10-Q · filed 2022-08-10 | $7.31M derived: sum of 3 quarters · filed 2022-08-10 | $9.20M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.40M 10-Q · filed 2022-05-10 | $4.49M derived: sum of 2 quarters · filed 2022-05-10 | $6.38M derived: sum of 3 quarters · filed 2022-05-10 | $8.13M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $3.98M derived: sum of 2 quarters · filed 2022-03-29 | $5.73M derived: sum of 3 quarters · filed 2022-03-29 | $7.78M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.89M 10-Q · filed 2021-11-09 | $3.64M derived: sum of 2 quarters · filed 2021-11-09 | $5.69M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $1.75M 10-Q · filed 2021-08-30 | $3.80M 10-Q · filed 2021-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |